A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement

Philip C. Comp, Thomas Voegeli, John W. McCutchen, Vasilios A. Skoutakis, Arthur Trowbridge, William L. Overdyke, Lynn Boynton, Gregory Wise, Hau Kwaan, Ronald W. Geckler, Michael Kalafer, Richard H White, Roger M. Lyons, Paul F. White

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.

Original languageEnglish (US)
Pages (from-to)1123-1128
Number of pages6
JournalOrthopedics
Volume21
Issue number10
StatePublished - Oct 1998
Externally publishedYes

Fingerprint

Hip Replacement Arthroplasties
Warfarin
Venous Thrombosis
Hip
Surgical Blood Loss
Fibrinolytic Agents
danaproid
Phlebography
Incidence
Risk Reduction Behavior
Thrombosis
Sodium
Clinical Trials
Injections

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Comp, P. C., Voegeli, T., McCutchen, J. W., Skoutakis, V. A., Trowbridge, A., Overdyke, W. L., ... White, P. F. (1998). A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. Orthopedics, 21(10), 1123-1128.

A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. / Comp, Philip C.; Voegeli, Thomas; McCutchen, John W.; Skoutakis, Vasilios A.; Trowbridge, Arthur; Overdyke, William L.; Boynton, Lynn; Wise, Gregory; Kwaan, Hau; Geckler, Ronald W.; Kalafer, Michael; White, Richard H; Lyons, Roger M.; White, Paul F.

In: Orthopedics, Vol. 21, No. 10, 10.1998, p. 1123-1128.

Research output: Contribution to journalArticle

Comp, PC, Voegeli, T, McCutchen, JW, Skoutakis, VA, Trowbridge, A, Overdyke, WL, Boynton, L, Wise, G, Kwaan, H, Geckler, RW, Kalafer, M, White, RH, Lyons, RM & White, PF 1998, 'A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement', Orthopedics, vol. 21, no. 10, pp. 1123-1128.
Comp PC, Voegeli T, McCutchen JW, Skoutakis VA, Trowbridge A, Overdyke WL et al. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. Orthopedics. 1998 Oct;21(10):1123-1128.
Comp, Philip C. ; Voegeli, Thomas ; McCutchen, John W. ; Skoutakis, Vasilios A. ; Trowbridge, Arthur ; Overdyke, William L. ; Boynton, Lynn ; Wise, Gregory ; Kwaan, Hau ; Geckler, Ronald W. ; Kalafer, Michael ; White, Richard H ; Lyons, Roger M. ; White, Paul F. / A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. In: Orthopedics. 1998 ; Vol. 21, No. 10. pp. 1123-1128.
@article{0e4780a0f0964af9a08407737b3fcd65,
title = "A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement",
abstract = "Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27{\%} of patients who received warfarin and 14.6{\%} of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46{\%}. The absolute difference in the incidence of deep vein thrombosis was 12.3{\%} in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5{\%} for danaparoid and 4.1{\%} for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.",
author = "Comp, {Philip C.} and Thomas Voegeli and McCutchen, {John W.} and Skoutakis, {Vasilios A.} and Arthur Trowbridge and Overdyke, {William L.} and Lynn Boynton and Gregory Wise and Hau Kwaan and Geckler, {Ronald W.} and Michael Kalafer and White, {Richard H} and Lyons, {Roger M.} and White, {Paul F.}",
year = "1998",
month = "10",
language = "English (US)",
volume = "21",
pages = "1123--1128",
journal = "Orthopedics",
issn = "0147-7447",
publisher = "Slack Incorporated",
number = "10",

}

TY - JOUR

T1 - A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement

AU - Comp, Philip C.

AU - Voegeli, Thomas

AU - McCutchen, John W.

AU - Skoutakis, Vasilios A.

AU - Trowbridge, Arthur

AU - Overdyke, William L.

AU - Boynton, Lynn

AU - Wise, Gregory

AU - Kwaan, Hau

AU - Geckler, Ronald W.

AU - Kalafer, Michael

AU - White, Richard H

AU - Lyons, Roger M.

AU - White, Paul F.

PY - 1998/10

Y1 - 1998/10

N2 - Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.

AB - Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.

UR - http://www.scopus.com/inward/record.url?scp=7344223314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344223314&partnerID=8YFLogxK

M3 - Article

C2 - 9801236

AN - SCOPUS:7344223314

VL - 21

SP - 1123

EP - 1128

JO - Orthopedics

JF - Orthopedics

SN - 0147-7447

IS - 10

ER -